Market Overview

Jefferies Reiterates Hold Rating, $6 PT for Exelixis

Share:
Related EXEL
Mid-Day Market Update: Red Hat Rises After Strong Q1 Results; CIRCOR Shares Slide
AVEO Reaches Enrollment Target in Pivotal Tivozanib Study
After Celgene, Regeneron Breakouts, This Biotech Stock May Be Next (Investor's Business Daily)

In a company update published earlier today, Jefferies & Company, Inc. reiterated its Hold rating and $6.00 price target for Exelixis, Inc. (NASDAQ: EXEL), related to the recent reveal of cabo NRE efficacy data.

Jefferies went on to say “The cabo NRE data, somewhat key for the mCRPC outlook and presented at ASCO, left much to be desired. Despite somewhat intriguing early data in renal and liver cancers for which further exploration is warranted, we remain concerned about cabo's clinical, regulatory and commercial prospects in mCRPC, where investor and EXEL's focus lies.”

Exelixis, Inc. closed yesterday at $4.77.

Latest Ratings for EXEL

DateFirmActionFromTo
Mar 2017NeedhamInitiates Coverage OnBuy
Mar 2017OppenheimerInitiates Coverage OnPerform
Feb 2017Stifel NicolausDowngradesBuyHold

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Jefferies & Company Inc.Analyst Color Reiteration Analyst Ratings

 

Related Articles (EXEL)

View Comments and Join the Discussion!